Market Synopsis:
The Neuropathic
Pain Market Overview and Analysis by Type ,by Indication
,by Diagnosis, by Treatment, by Distribution Channel ,by End user and Region.
As per Market Research Future (MRFR)’s latest analysis, the global neuropathic pain
market is set to proliferate at a CAGR of
9.10% during the forecast period. The rising
prevalence of chronic diseases such as diabetes and cancer that triggers
neuropathic pain is a major factor responsible
for driving the growth of the market.
The developments in the healthcare sector
coupled with rising disposable income has led to an unprecedented growth of the
healthcare expenditure over the years. This,
in turn, is prognosticated to catalyze the expansion of the global neuropathic
pain market over the assessment period.
The development of pain management centers
is another major factor responsible for the proliferation of the
neuropathic pain market through the projection period. The fast-developing
economies resonate strong growth opportunities for the market players.
Additionally, favorable reimbursement policies are likely to accelerate revenue
creation for the players of the market across the assessment period. However,
lack of awareness and increase in the dealings of counterfeit drugs are expected to hold the growth of the neuropathic
pain market in the coming years.
Market
Segmentation:
By type, the neuropathic pain market is segmented into peripheral neuropathy,
entrapment neuropathy, post-traumatic
neuropathy, phantom limb pain, post-herpetic
neuralgia (PHN), and trigeminal neuralgia.
By indication, the market is segmented into spinal stenosis, diabetic neuropathy, and chemotherapy-induced peripheral
neuropathy treatment.
By diagnosis, the global neuropathic pain market size has been segmented into imaging, blood tests, and physical examination.
By treatment, the market is segmented into multimodal therapy and
medication type. The medication type segment is
further sub-segmented into anticonvulsants, nephrogenic syndrome of
inappropriate antidiuresis (NSAIDs) type, nerve blocks type, and antidepressant
drugs type.
By distribution channel, the neuropathic
pain market has been segmented into
retail pharmacies & drug stores, and online pharmacies.
By end user, the global neuropathic pain
market is segmented into hospitals,
clinics, and research organizations.
Regional Analysis:
By region, the global neuropathic pain
market size has been segmented into Americas, Europe, Asia Pacific, and the Middle
East & Africa. Americas is poised to dominate the global market towards the
end of the forecast period registering a CAGR of 5.36% over 2023. The factors
responsible for favoring the growth of the market include developed healthcare
infrastructure, rising healthcare expenditure, and increasing initiatives
undertaken by the governments. Meanwhile, Europe is closely competing with Americas
and is estimated to reach a valuation of USD 2,844.49 Mn over 2023.
Asia Pacific is set to register a
relatively higher CAGR of 6.76% during the forecast period. The revamping of
the healthcare sector in the region is projected to augment the neuropathic
pain market in the foreseeable future. Meanwhile, the Middle East & Africa
resonates strong opportunities for growth
and is prognosticated to expand at 6.45% CAGR in the forthcoming years.
Competitive
Dashboard:
Some of the key players
profiled in the
report are Eli Lilly and Company (U.S.), Biogen Inc. (U.S.), Baxter Healthcare
Corporation (U.S.), Johnson & Johnson Services Inc. (U.S.), Astellas Pharma
Inc. (Tokyo), Pfizer, Inc. (U.S.), Abbott Laboratories (U.S.), Sanofi S.A.
(France), AstraZeneca (U.K.), GlaxoSmithKline plc (U.K.), and Depomed Inc.
(U.S.).
Industry
Developments:
In October 2018, New Jersey Health
Foundation (NJHF)’s HealthStartNJ invested USD 50,000in Paracelsus
Neuroscience, a startup that focuses on the study and therapeutics of
neuropathic pain.
In October 2018, Selexis, a global leader in mammalian cell line
development, and Hoba Therapeutics, for advancing the development of Hoba’s
clinical candidate HB-086 (rhMeteorin)
for the effective treatment of peripheral neuropathic pain.
In October 2018, scientists at Scripps
Research have identified a molecular target in neurons, PIEZO2, for neuropathic
pain.
At
Market Research Future (MRFR), we enable our customers to unravel the
complexity of various industries through our Cooked Research Report (CRR),
Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have
supreme objective to provide the optimum quality market research and
intelligence services to our clients.
Contact us:
Market Research Future (part of Wantstats Research
and Media Private Limited),
99 Hudson Street, 5Th Floor,
New York, New York 10013
United States of America
+1 628 258 0071
Email: sales@marketresearchfuture.com
0 Comments